The 10th International MDM2 Workshop
第十届国际MDM2研讨会
基本信息
- 批准号:10814471
- 负责人:
- 金额:$ 1.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-15 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcetylationAfrican AmericanAntineoplastic AgentsApoptosisAreaAwardBasic ScienceBindingBiologyCOVID-19Cancer BiologyCancer CenterCareer MobilityCell Cycle ProgressionChildCitiesClinical ResearchClinical TrialsCollaborationsCommunitiesComplexDNA RepairDoctor of PhilosophyDrug IndustryDrug TargetingEducational workshopEnsureEuropeEventFloridaFundingGene DeletionGene MutationGenesGenetic TranscriptionGoalsGrantHispanicHomologous GeneHumanImmunityIn VitroIndividualInternationalJapanLocationMDM2 Gene AmplificationMDM2 geneMalignant NeoplasmsMediatingMedicineMentorsMinorityMutateNCI Center for Cancer ResearchNew YorkOncogenicParticipantPathway interactionsPharmaceutical PreparationsPhosphorylationPlayPostdoctoral FellowProteinsPublic HealthReagentRegulationResearchResearch InstituteResearch PersonnelRoleScientistSenior ScientistSignal TransductionSingaporeStudentsTP53 geneTokyoTranslational ResearchTravelTumor Suppressor ProteinsUbiquitinationUnderrepresented MinorityUnderrepresented PopulationsUnited KingdomUnited StatesUniversitiesUp-RegulationWomanWritinganti-PD-L1anticancer researchcancer immunotherapycareerclinically relevantcollegedesigndrug discoverygraduate studentin vivoinhibitorinterdisciplinary approachmanmedical schoolsmeetingsmouse modeloverexpressionpatient subsetspublic health relevanceresponsesocialtumorubiquitin-protein ligase
项目摘要
Project Summary/Abstract
The p53 protein is the most frequently mutated gene in human cancers and functions as a tumor suppressor by
transcriptionally regulating numerous downstream target genes involved in cell cycle progression and apoptosis.
MDM2 and its homolog MDM4 (also known as MDMX) are two of the most important negative regulators of p53
by acting as an E3 ubiquitin ligase complex to promote p53 degradation and by physical binding to inhibit the
p53’s transcriptional function. These proteins are also overexpressed in approximately 30% of human cancers.
Overexpression of MDM2/MDM4 not only inhibits p53 function, but also shows p53-independent oncogenic
activities. Intriguingly, gene amplification of MDM2 and MDM4 is associated with adverse hyperprogressive
response to anti-PDL1 cancer immunotherapy in a subset of patients. Thus, inhibitors for MDM2 and MDM4
have been developed to inhibit their oncogenic activities and to reactivate wild-type p53 in tumors. Importantly,
some MDM2/MDM4 inhibitors are in clinical trials. The first International MDM2 Workshop, held in 2001 in the
United Kingdom, was primarily in response to a significant increase in the research related to p53 and its negative
regulators MDM2/MDM4, as well as strong demand for drug discovery targeting MDM2/MDM4/p53. The
expansion of the scientific community studying MDM2/MDM4 and the need to pursue this area of research with
a collaborative multidisciplinary approach have further made the MDM2 Workshop necessary. The MDM2
Workshop is held every two or three years, at locations alternating between the United States and Europe, to
bring together the p53/MDM2 field, present the latest research, and facilitate collaboration and exchange of
reagents. Indeed, both the p53 and MDM2 Workshops have become important platforms for long-term scientific
exchange and new investigators of the MDM2-p53 pathway. The 10th International MDM2 Workshop will be held
at an auditorium of the newly built National Cancer Center Research Institute (NCCRI) in Tokyo, Japan, on
October 15-18, 2023. This will be the first International p53/MDM2 Workshop organized and held in Japan. The
meeting will be co-organized by Dr. Rieko Ohki (NCCRI, Tokyo, Japan), Dr. Koji Itahana (Duke-NUS Medical
School, Singapore), and Dr. Tomoo Iwakuma (Children’s Mercy Research Institute, MO, USA). Notably, due to
COVID-19, we have not had the MDM2 Workshop for over 4 years, since the 9th MDM2 Workshop on November
4-7, 2018 in Florida. We expect more participants with higher enthusiasm for this 10th MDM2 Workshop, as
compared with the previous MDM2 Workshops. Significant numbers of US researchers, including the
international organizing committee (11 out of 16, 38% women), are expected to participate in and benefit from
the meeting. Hence, we are applying for R13 funding to support this important and exciting international meeting
that will energize research in US and promote scientific progress and interactions in the p53/MDM2 field. Funds
are requested to support three important specific aims designed to promote participation of the US investigators
and trainees.
项目总结/摘要
p53蛋白是人类癌症中最常见的突变基因,通过以下途径发挥肿瘤抑制因子的作用:
转录调节许多参与细胞周期进程和凋亡的下游靶基因。
MDM 2及其同源物MDM 4(也称为MDMX)是p53的两种最重要的负调节剂
通过作为E3泛素连接酶复合物促进p53降解和通过物理结合抑制p53降解,
p53的转录功能。这些蛋白质在大约30%的人类癌症中也过表达。
MDM 2/MDM 4的过表达不仅抑制p53功能,而且表现出p53非依赖性致癌作用。
活动有趣的是,MDM 2和MDM 4的基因扩增与不良的过度进展相关。
在一个患者子集中对抗PDL 1癌症免疫疗法的反应。因此,MDM 2和MDM 4的抑制剂
已被开发用于抑制它们的致癌活性并重新激活肿瘤中的野生型p53。重要的是,
一些MDM 2/MDM 4抑制剂正在进行临床试验。2001年,第一届国际MDM 2研讨会在
英国,主要是为了应对与p53及其负相关的研究的显著增加。
调节剂MDM 2/MDM 4,以及对靶向MDM 2/MDM 4/p53的药物发现的强烈需求。的
* 扩大科学界对MDM 2/MDM 4的研究,并需要继续进行这一领域的研究,
多学科协作方法进一步使第二次千年发展目标讲习班成为必要。述mdm 2
讲习班每两年或三年在美国和欧洲轮流举办,
汇集p53/MDM 2领域,展示最新研究,促进合作和交流,
试剂事实上,p53和MDM 2研讨会已经成为长期科学研究的重要平台。
MDM 2-p53通路的交流和新的研究者。第10届国际MDM 2研讨会将于
在日本东京新建的国家癌症中心研究所(NCCRI)的礼堂,
2023年10月15日至18日。这将是第一次在日本举办的国际p53/MDM 2研讨会。的
会议将由Rieko Ohki博士(日本东京NCCRI)、Koji Itahana博士(杜克-NUS医疗
学校,新加坡)和岩沼友雄博士(美国密苏里州儿童慈善研究所)。值得注意的是,由于
COVID-19,自11月9日第九届MDM 2研讨会以来,我们已经超过4年没有举办MDM 2研讨会了
2018年4月7日在佛罗里达。我们期待更多的参与者以更高的热情参加第十届MDM 2研讨会,
与以前的MDM 2研讨会相比。大量的美国研究人员,包括
国际组织委员会(16人中有11人,妇女占38%),预计将参加并受益于
了那次会议因此,我们正在申请R13资金,以支持这一重要而令人兴奋的国际会议
这将激励美国的研究,促进p53/MDM 2领域的科学进步和相互作用。资金
要求支持旨在促进美国调查人员参与的三个重要具体目标
和实习生。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
"The 10th International MDM2 Workshop": Opening up new avenues for MDM2 and p53 research, the First International MDM2 Workshop in Asia.
“第十届国际MDM2研讨会”:为MDM2和p53研究开辟新途径,亚洲首届国际MDM2研讨会。
- DOI:10.1111/gtc.13114
- 发表时间:2024
- 期刊:
- 影响因子:0
- 作者:Ohki,Rieko;Itahana,Koji;Iwakuma,Tomoo
- 通讯作者:Iwakuma,Tomoo
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tomoo Iwakuma其他文献
Tomoo Iwakuma的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tomoo Iwakuma', 18)}}的其他基金
Control of mutant p53 stability via the mevalonate pathway-DNAJA1 axis
通过甲羟戊酸途径-DNAJA1 轴控制突变体 p53 的稳定性
- 批准号:
10320158 - 财政年份:2021
- 资助金额:
$ 1.5万 - 项目类别:
Control of mutant p53 stability via the mevalonate pathway-DNAJA1 axis
通过甲羟戊酸途径-DNAJA1 轴控制突变体 p53 的稳定性
- 批准号:
10339474 - 财政年份:2021
- 资助金额:
$ 1.5万 - 项目类别:
Control of mutant p53 stability via the mevalonate pathway-DNAJA1 axis
通过甲羟戊酸途径-DNAJA1 轴控制突变体 p53 的稳定性
- 批准号:
9523990 - 财政年份:2018
- 资助金额:
$ 1.5万 - 项目类别:
The role of MDM2-MTBP axis in cancer metastasis
MDM2-MTBP轴在癌症转移中的作用
- 批准号:
8694358 - 财政年份:2014
- 资助金额:
$ 1.5万 - 项目类别:
The role of MDM2-MTBP axis in cancer metastasis
MDM2-MTBP轴在癌症转移中的作用
- 批准号:
8842602 - 财政年份:2014
- 资助金额:
$ 1.5万 - 项目类别:
DISSECTING ROLES OF MTBP IN OSTEOSARCOMA METASTASIS
剖析 MTBP 在骨肉瘤转移中的作用
- 批准号:
7720778 - 财政年份:2008
- 资助金额:
$ 1.5万 - 项目类别:
DISSECTING ROLES OF MTBP IN OSTEOSARCOMA METASTASIS
剖析 MTBP 在骨肉瘤转移中的作用
- 批准号:
7610681 - 财政年份:2007
- 资助金额:
$ 1.5万 - 项目类别:
UNCOVERING THE MECHANISMS OF OSTEOSARCOMA METASTASIS SUPPRESSION BY MTBP
揭示 MTBP 抑制骨肉瘤转移的机制
- 批准号:
8168370 - 财政年份:2004
- 资助金额:
$ 1.5万 - 项目类别:
UNCOVERING THE MECHANISMS OF OSTEOSARCOMA METASTASIS SUPPRESSION BY MTBP
揭示 MTBP 抑制骨肉瘤转移的机制
- 批准号:
8360720 - 财政年份:2004
- 资助金额:
$ 1.5万 - 项目类别:
DISSECTING ROLES OF MTBP IN OSTEOSARCOMA METASTASIS
剖析 MTBP 在骨肉瘤转移中的作用
- 批准号:
7960535 - 财政年份:2004
- 资助金额:
$ 1.5万 - 项目类别:
相似海外基金
Broadening Participation Research: Understanding faculty attitudes, competency, and perceptions of providing career advising to African American STEM students at HBCUs
扩大参与研究:了解教师对 HBCU 的非裔美国 STEM 学生提供职业建议的态度、能力和看法
- 批准号:
2306671 - 财政年份:2023
- 资助金额:
$ 1.5万 - 项目类别:
Continuing Grant
Cognitive Behavioral Faith-based Depression Intervention For African American Adults (CB-FAITH): An Effectiveness And Implementation Trial
非裔美国成年人基于认知行为信仰的抑郁干预 (CB-FAITH):有效性和实施试验
- 批准号:
10714464 - 财政年份:2023
- 资助金额:
$ 1.5万 - 项目类别:
DELINEATING THE ROLE OF THE HOMOCYSTEINE-FOLATE-THYMIDYLATE SYNTHASE AXIS AND URACIL ACCUMULATION IN AFRICAN AMERICAN PROSTATE TUMORS
描述同型半胱氨酸-叶酸-胸苷酸合成酶轴和尿嘧啶积累在非裔美国人前列腺肿瘤中的作用
- 批准号:
10723833 - 财政年份:2023
- 资助金额:
$ 1.5万 - 项目类别:
Preventing Firearm Suicide Deaths Among Black/African American Adults
防止黑人/非裔美国成年人因枪支自杀死亡
- 批准号:
10811498 - 财政年份:2023
- 资助金额:
$ 1.5万 - 项目类别:
Exploring PTSD Symptoms, Barriers and Facilitators to Mindfulness-based Stress Reduction for Justice-Involved Black/African American Female Adolescents and Parents/Caregivers
探索创伤后应激障碍 (PTSD) 症状、障碍和促进因素,为涉及正义的黑人/非裔美国女性青少年和父母/照顾者进行基于正念的减压
- 批准号:
10593806 - 财政年份:2023
- 资助金额:
$ 1.5万 - 项目类别:
BCSER - PVEST: A Dynamic Framework for Investigating STEM Interest, Attitude and Identity Among African American Middle School Students
BCSER - PVEST:调查非裔美国中学生 STEM 兴趣、态度和身份的动态框架
- 批准号:
2327055 - 财政年份:2023
- 资助金额:
$ 1.5万 - 项目类别:
Standard Grant
Making the Connection: Understanding the dynamic social connections impacting type 2 diabetes management among Black/African American men
建立联系:了解影响黑人/非裔美国男性 2 型糖尿病管理的动态社会联系
- 批准号:
10782674 - 财政年份:2023
- 资助金额:
$ 1.5万 - 项目类别:
Building a Community-Based Mental Health Literacy Intervention for African American Young Adults
为非裔美国年轻人建立基于社区的心理健康素养干预措施
- 批准号:
10738855 - 财政年份:2023
- 资助金额:
$ 1.5万 - 项目类别:
African American Literature in "post" Post-Racial America
“后”后种族美国中的非裔美国文学
- 批准号:
23K00376 - 财政年份:2023
- 资助金额:
$ 1.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Impact of a Race-Based Stress Reduction Intervention on Well-Being, Inflammation, and DNA methylation in Older African American Women at Risk for Cardiometabolic Disease
基于种族的减压干预措施对有心血管代谢疾病风险的老年非洲裔美国女性的健康、炎症和 DNA 甲基化的影响
- 批准号:
10633624 - 财政年份:2023
- 资助金额:
$ 1.5万 - 项目类别: